Please login to get additional information, such as SOLANEZUMAB development phases.

Not a member yet? Sign Up here, it's free!

Solanezumab is a monoclonal antibody that binds specifically to soluble amyloid beta and thereby alters the sticky characteristics of this peptide. Alzheimer's disease theory suggests that amyloid beta kills brain cells. Clinical studies have examined the ability of Solanezumab to impact amyloid beta in blood and cerebrospinal fluid and found significant dose-dependent changes. To date, the most frequently occurring side effect experienced in clinical studies with Solanezumab has been mild chills consistent with an infusion reaction.
Drug information
Highest Dev Status Phase 2
Therapeutic AreaCentral Nervous System
Potential Indications Please Login
Identified Action Mechanisms1
Literature NCBI